# BioBots

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biobots

- Industry: Business Support Services
- Headquarters: Philadelphia, US
- Website: www.biobots.io
- Total disclosed funding: $1.3M
- Latest round: Seed (May 6, 2015)
- Investors on record: 3

## About

BioBots specializes in innovative bioprinting technologies that enable the creation of human-relevant biological structures for healthcare and life sciences, enhancing research capabilities in regenerative medicine and tissue engineering.Founded in 2014 in Philadelphia, US, BioBots operates in the bioprinting sector, offering advanced solutions for building biological structures. The company was founded by Mariana Matus, who serves as CEO, and has undergone strategic development to enhance its operational capabilities. BioBots has raised a total of USD 1.20 mn across 4 deals, with its most recent funding round being Venture Debt, raising USD 1.25 mn on June 7, 2016, from investors including 500 Global, Ben Franklin Technology Partners, DreamIt Ventures, and FundersClub.BioBots focuses on developing and commercializing innovative bioprinting technologies, particularly its flagship product, the BioAssemblyBot (BAB). The BAB is an advanced 3D bioprinter designed to assemble biological structures, aiding researchers in creating organoids and tissues with native vascular perfusion. This technology leverages over 60 years of industrial robotic innovation for high precision and efficient manufacturing, catering to drug discoverers, tissue engineers, device developers, and academic researchers, mainly across North America and Europe.BioBots generates revenue through direct sales and partnerships related to its BioAssemblyBot platform. Transactions are primarily B2B, with clients purchasing various models of the BioAssemblyBot and associated software solutions, like TSIM and BioApps, which enhance biofabrication capabilities. The pricing varies based on model specifications, ensuring a wide range of client needs are catered to.BioBots is actively designing new products to enhance its bioprinting capabilities and plans to expand into new global markets by 2018. The recent funding raised in June 2016 will support these initiatives, allowing for the development of additional bioprinting solutions and facilitating entry into targeted geographic areas.

## Funding rounds

- Seed, May 6, 2015, $1.2M — Ben Franklin Technology Partners, BioAdvance
- Seed, Aug 8, 2014, $0.1M — DreamIt Ventures

## Investors

- DreamIt Ventures (https://capitalatlas.ai/funds/dreamit-ventures) — Seed
- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Seed
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed